Nanobiotix SA logo

Nanobiotix SA

NBTX
Healthcare|Biotechnology|France
$39.95
+1.12 (+2.88%)

About

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Stock Price

+663.9%(1Y)

Pipeline Summary

7 total trials
5
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
Completed: 2Recruiting: 1Terminated: 2Unknown: 1Active: 1

Active Trials (2)

NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer
NCT07224152Locally-Advanced Non-Small Cell Lung Cancer
Phase 1Phase 2Recruiting
Enrollment: 40 participants
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
NCT03589339Radiotherapy
Phase 1Active
Enrollment: 145 participants

BioScore

5.8/10
Watchlist

Ownership

Data last updated: Jul 13, 2026, 12:43 PM